Vectorbuilder Inc

Activities: Research & Development

Trending Articles

  1. NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant...
  2. Isopod Rapid Cleanrooms: the ideal elite controlled environment pod solution for Life Sciences and Engineering start-ups The Guardtech Group’s quick-assembly cleanroom pods combine superior performance, build quality and cost-effectiveness to give new applications the perfect platform to get...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Delivering precision: why advanced therapies are redefining pharmaceutical logistics As advanced therapies narrow tolerances and personalise care, pharmaceutical logistics is being redefined as a precision-driven extension of treatment delivery, writes Michael...
  4. Nose-to-brain delivery outperforms systemic BBB technologies according to MetP Pharma The pioneering company has published preclinical data that strongly supports the advantages of its proprietary nose-to-brain drug delivery technology compared with systemic...
  5. AstraZeneca strengthens weight management pipeline with CSPC Pharmaceuticals collaboration The pair have signed a strategic collaboration covering eight obesity and type 2 diabetes programmes, including a clinical-ready GLP-1/GIP asset, AI-driven peptide discovery...

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

Related Content

Manufacturing

Why has gene delivery become such a hot property?

VectorBuilder's latest cash injection drives them towards a CDMO facility for the manufacturing of plasmids, mRNA, AAV, lentivirus, cell lines, and a variety of viral and non-viral vectors
Manufacturing

Plasmid and lentiviral vector CDMO VectorBuilder orders rise by 70%

The company's plasmid and lentiviral vector CDMO products have received Investigational New Drug (IND) approval from the FDA
Research & Development

VectorBuilder to construct R&D and manufacturing campus

Construction is expected to cost $500m and will be split into two phases over the next four years
Subscribe now